Absolutely nothing
Glutamate is thought to enter insulin secretory vesicles and to promote exocytosis of the vesicles [67]
Alternative strategies to harness the glucose-lowering action of GLP-1 Besides the production of formulations of GLP-1 receptor agonists with longer durations of action, other strategies for harnessing the glucose-lowering actions of GLP-1 have been developed
3a,b) and HOMA-IR (Extended Data Fig
The STEP trials demonstrated average weight loss of 9.2-15% over 68 weeks depending on dose, with the highest doses producing losses exceeding 35 pounds on average
India, known as the pharmacy of the world, has a significant opportunity to play a pivotal role in the GLP-1 space With the growing global demand for weight loss drugs, Indian CDMOs must leverage these strengths to scale up device manufacturing, focusing on cost-efficient, high-quality drug delivery systems that can serve both the large domestic market and emerging global economies. Convergence of sustainability and scalability The rise in demand has put a spotlight on environmental sustainability